We caught up with Dr. Vincent Joustra (AGEM University of Amsterdam, Amsterdam, The Netherlands) around his cohort study investigating predictive biomarkers for response to vedolizumab in Crohn’s disease.
The abstract entitled ‘Peripheral blood DNA methylation biomarkers accurately predict clinical- and endoscopic response to vedolizumab in a real-life cohort of Crohn’s Disease patients’ (Presentation no. OP29) was presented at the 17th Congress of ECCO, February 16-19, 2022!
- Why is there a need for predictive biomarkers for response to vedolizumab in Crohn’s disease? (0:59)
- What were the aims, design and inclusion criteria of the cohort study you are presenting? (2:38)
- What were the findings in terms of biomarker identification? (4:14)
- How easy will it be to incorporate analysis of these biomarkers into routine clinical practice? (5:18)
- What questions remain unanswered and what future studies are planned? (6:57)
Disclosures: Vincent Joustra has nothing to disclose in relation to this interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ECCO-IBD virtual 2022.
Share this Video
Related Videos In Gastroenterology
Jayne Doherty, UEG Week 2022: Response to COVID-19 vaccination in patients with inflammatory bowel disease taking TNF antagonists
In this touchIMMUNOLOGY interview, we speak with Dr. Jayne Doherty (St Vincent’s University Hospital, Dublin, Ireland) around her study, which investigated the impact of inflammatory bowel disease (IBD) and of TNF inhibitor therapy for treatment of IBD on antibody responses to vaccination against COVID-19. The abstract entitled ‘REDUCED SEROLOGICAL RESPONSE TO COVID-19 BOOSTER VACCINES IN […]
Gil Melmed: Research highlights in inflammatory bowel disease from 2022
In 2022, 3 therapies were approved for the treatment of the inflammatory bowel diseases Crohn’s disease and ulcerative colitis. including a JAK inhibitor, and s1P receptor modulator in UC and an IL-23 inhibitor in Crohn’s disease. Advances in research in combination therapy and personalised medicine were also at the forefront in 2022. It was a […]
Gil Melmed: Health burden and available therapies for Crohn’s disease and colitis
touchIMMUNOLOGY caught up with expert faculty member Dr. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) to learn more around the health burden of Crohn’s disease and colitis and what therapies are currently available to help manage symptoms in these indications. Questions Could you give us a brief overview of the health burden of Crohn’s […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!